ClinicalTrials.gg

Osteoarthritis, Knee clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 3,296 studies for Osteoarthritis, Knee across more than 10 countries. 625 are recruiting or about to start. 3,057 of them are mainly about Osteoarthritis, Knee (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 4,560 studies for Osteoarthritis, Knee. How that becomes 3,294 here

This page counts the studies the registry files under Osteoarthritis, Knee, and those it files under no condition that list Osteoarthritis, Kneethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 4,560Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −40List Osteoarthritis, Knee as a condition, but the registry did not file them under itMost often written as “Bilateral Knee Osteoarthritis” (3), “Osteoarthritis Knees Both” (3), and “Post-Traumatic Osteoarthritis of Knee” (3). The registry filed them under other conditions only, most often Osteoarthritis (35) and Pain (6).
  3. −1,226Match it another way504 name it in the title, 4 in a keyword, and 718 by a synonym or other text the search reads.
  4. 3,294The count on this page59 of them list Osteoarthritis, Knee in their own words; the registry filed them under no condition.

Status

Completed
1,844
Status unknown
450
Recruiting
385
Not yet recruiting
213
Active, not recruiting
154
Terminated
135

Phase

Phase 2
355
Phase 3
271
Phase 4
229
Phase 1
175
Early Phase 1
27

Where

United States
796
Turkey
268
Canada
171
China
136
Pakistan
135
France
124

Who develops what

Add Osteoarthritis, Knee to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 24 programs from 22 companies, 20 with this as their studies’ main aim; 9 with a live phase 3 study; 10 primary completions in the next 12 months. Compare Jiangsu HengRui Medicine, Laboratorios Silanes S.A. de C.V. and Eli Lilly here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
CelecoxibRecent, repeated
Evidence
  • NCT06863636 · Laboratorios Silanes S.A. de C.V. · Phase 3 · comparator · “Celecoxib” · registered Mar 2025
  • NCT05930080 · SK Chemicals Co., Ltd. · Phase 3 · comparator · “Celebrex” · registered Jun 2023
  • NCT05324163 · Jiangsu XinChen-Techfields Pharma Co., LTD. · Phase 3 · comparator · “Celecoxib capsules” · registered Apr 2022
  • NCT03949673 · Regeneron Pharmaceuticals · Phase 2 · background · “Celecoxib” · registered Apr 2019
  • NCT03850587 · yooyoung pharmaceutical co ltd · Phase 2 · comparator · “Celecoxib 200mg” · registered Feb 2019
Viatris Inc.41% of its industry studiesUS: off-patent, 16 generics marketed33 studies

12 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
SL1002☆ Track1 live phase-3 study: NCT07226258Saol Therapeutics Inc
Plectin-1 Targeting Agent PTP-01☆ Track1 live phase-3 study: NCT07219771Doron Therapeutics Inc.
Hyaluronic AcidPhase 4 trial recorded☆ Track1 live phase-3 study: NCT07819461IBSA Institut Biochimique SA
Pentosan Polysulfate Sodium twice weekly☆ Track1 live phase-3 study: NCT06917404Paradigm Biopharmaceuticals Ltd.
ecnoglutide☆ Track1 live phase-3 study: NCT07734311Hangzhou Sciwind Biosciences Co., Ltd.

The 5 in phase 3 with the nearest primary completion, of 24 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (10)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.enekinragene inzadenovec · Pacira BioSciences, Inc. · Phase 2 main aimNCT06884865 A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee — primary endpoint: Incidence (number and percent) of treatment-emergent adverse events (TEAEs) for PCRX-201 Dose A and Dose B versus placebo from Week 1 through Week 52 · 135 enrolled
  • 30 Nov 2026 est.SL1002 · Saol Therapeutics Inc · Phase 3 main aimNCT07226258 Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain — primary endpoint: Change From Baseline to Week 12 in the Weekly Mean of the Average Daily Pain Intensity While Walking · 150 enrolled
  • 30 Nov 2026 est.NCR100 · Nuwacell Biotechnologies Co., Ltd. · Phase 2 main aimNCT06741098 A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis( KOA) — primary endpoint: Dose-Limiting Toxicity(DLT) · 162 enrolled

7 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Osteoarthritis, Knee studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here NSAIDs 6 open · Corticosteroids 5 open · SNRIs 4 open · Local anesthetics 3 open · Antifibrinolytics 2 open

Coming up

235studies finish main data collection within a year11 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 385 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 114 (30%) stop at 75 or younger. 19 (5%) take children under 18. 12 (3%) are for women only and 0 (0%) for men only; 39 (10%) take healthy volunteers.

Recruiting studies that take each age, of 385
AgeWomenMen
1015 (4%)15 (4%)
18147 (38%)146 (38%)
30183 (48%)181 (47%)
40279 (72%)275 (71%)
50359 (93%)349 (91%)
65359 (93%)348 (90%)
75309 (80%)303 (79%)
85221 (57%)217 (56%)

Across all 3,296 studies, recruiting or not: 31% stop at 75 or younger and 11% at 65; 5% take children; 3% are for women only and <1% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Osteoarthritis, Knee studies take

Of 101 phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 120 mo11–44 · 61 studies13 mo9–21 · 34 studies—
Phase 1/225 mo16–47 · 39 studies——
Phase 220 mo12–39 · 101 studies19 mo12–25 · 58 studies30 mo11–61 · 43 studies
Phase 2/331 mo11–43 · 18 studies——
Phase 322 mo15–35 · 101 studies20 mo13–27 · 65 studies32 mo17–50 · 36 studies
Phase 419 mo10–36 · 97 studies—19 mo10–32 · 88 studies
Interventional, no phase18 mo8–36 · 1,253 studies17 mo10–34 · 140 studies18 mo8–36 · 1,113 studies
Observational24 mo14–61 · 220 studies—24 mo12–48 · 179 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered35

Show 30 more

Studies

Recruiting first, then most recently updated. Showing 50 of 3,296. Browse all 3,296 → or search them.